Comparative genomic hybridization (CGH) using 40 cell lines derived from malignant melanomas (MMs) revealed frequent amplification at 7q33-q34 containing BRAF gene, which often is mutated in MM. We found this gene to be amplified to a remarkable degree in the MM cell lines that exhibited high-level gains at 7q33-q34 in CGH. Among 40 cell lines, the eight lines that revealed neither BRAF nor NRAS mutations showed even higher levels of BRAF mRNA expression than the 32 mutated lines, although DNA amplification at 7q33-q34 was not detected in every lines overexpressing BRAF. MM cells that carried wild-type BRAF and NRAS showed constitutive overexpression of B-Raf protein and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), even after serum starvation. Not only downregulation of the endogenously overexpressed wild-type B-Raf by antisense oligonucleotide but also a treatment with an inhibitor of mitogen-activated protein kinase kinase (MAPKK, MEK) reduced phosphorylated ERK1/2 and cell growth, whereas the exogenously expressed wild-type B-Raf promoted cell growth in MM cells. Our results provide the evidence that overexpression of wild-type B-Raf, in part but not always as a result of gene amplification, is one of the mechanisms underlying constitutive activation of the MAPK pathway that stimulates growth of MM cells.
Introduction
Malignant melanoma (MM) is one of the most virulent forms of cancer in humans. Recent advances in research have identified some of the genetic alterations involved in its development and progression (Sauter and Herlyn, 1998; Herlyn et al., 2000) . However, discoveries reported to date are not likely to account fully for the molecular pathogenesis of MM. Identification of additional genetic alterations could provide appropriate biomarkers for diagnosis and suggest molecular targets for therapy in the clinical management of MM.
Accumulated evidence suggests that multiple genetic alterations occurring sequentially in a cell lineage underlie the carcinogenetic process in solid tumors (Vogelstein and Kinzler, 1993) . Amplification of chromosomal DNA is one of the mechanisms capable of activating genes whose aberrant expression is a critical feature of progression of various types of cancer. Comparative genomic hybridization (CGH) (Kallioniemi et al., 1992) has proven to be an useful technique for identifying novel regions of amplification. Although CGH studies have revealed a variety of chromosomal aberrations in MM (Bastian et al., 1998; Balazs et al., 2001) , only one gene, CCND1, within an amplicon at 11q13, has been identified so far as a target oncogene in acral melanomas (Sauter et al., 2002) .
In the work reported here, we examined 40 MM cell lines by CGH to explore genomic alterations that might affect the development and progression of this tumor, and identified high-level gains (HLGs), indicative of gene amplification, in several chromosomal regions. Among them, amplification of the 7q33-q34 region focused our interest because it contains BRAF, a gene that is frequently mutated in MM (Brose et al., 2002; Davies et al., 2002; Pollock et al., 2003) . B-Raf functions in the RAS-RAF-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway, which mediates cellular responses to growth signals (Peyssonnaux and Eyche'ne, 2001) ; abnormalities of the mitogen-activated protein kinase (MAPK) pathway are known to be involved in the pathogenesis of MM and other tumors (Roelofs et al., 2000; Hoa et al., 2002; Smalley, 2003) . Moreover, continuous RAS activity is required for both the development and maintenance of MM in transgenic mice (Chin et al., 1999) , indicating that activation of the RAS-RAF-MEK-ERK pathway may have an essential role in melanomagenesis. Not only oncogenic mutations of KRAS2, but amplification and consequent overexpression of even wild-type KRAS2 also were shown to contribute to tumor growth (Hoa et al., 2002) . Since approximately 20% of MM showed no mutations of either RAS (NRAS and KRAS2) or BRAF (Brose et al., 2002; Davies et al., 2002; Pollock et al., 2003) , and amplification of RAS was rare in this disease (Bastian et al., 1998; Balazs et al., 2001) , we further investigated the status of BRAF in MM cells with respect to mutation, expression, and amplification. Our results suggest that endogenous overexpression of even nonmutated B-Raf may have an important role in promoting the growth of MM cells.
Results

Common regions involved in DNA copy-number aberrations in MM cell lines
To explore chromosomal regions that may harbor gene(s) critical to the melanomagenesis, we first carried out a CGH analysis of 40 MM cell lines ( Figure 1a) . Most of the lines (39/40, 97.5%) showed copy-number aberrations, with gains predominating over losses by a ratio of 2 : 1. On average, 10.8 (range, 0-27) aberrations were observed per cell line: 7.2 (range, 0-15) gains and 3.6 (range, 0-16) losses.
Minimal common regions for the most frequent copynumber gains were at 20q12-qter (26 cell lines of the total, 65.0%); 7q31-q34 (21, 52.5%); 7p15 (20, 50.0%); 1q31 and 15q25 (13 each, 32.5%); and 3q26.1 (12, 30.0%). Minimal common losses were seen at 9p and 10q25-qter (13 each, 32.5%). The smallest regions of HLGs involved 20q13.1 (nine cases); 7q33-q34 (six cases); 1q31, 5p13, and 20p12-pter (three cases each); and 3p12-p14 and 15q25 (two cases each).
Frequent amplification of BRAF in MM cell lines
Among the alterations observed frequently in our and previously reported CGH analyses (Bastian et al., 1998; Balazs et al., 2001) , gains of DNA at 7q, especially 7q33-34, are of particular interest, because the BRAF gene is located there. To confirm whether BRAF is the individual target of the 7q33-q34 amplification, we performed fluorescence in situ hybridization (FISH) analysis on the six MM lines that had exhibited HLG of this region (Figure 1a, b) . P1-derived artificial chromosome (PAC) RP5-839B19, containing part of the BRAF gene (exons 2 and 3), generated a remarkable increase in FISH signals in C32mel (Figure 1c ) and the other five lines as well (397mel, 537mel, 729mel, SK-MEL-23, and SK-MEL-28; data not shown), indicating unambiguously that BRAF locates within the amplicon.
Mutation status of BRAF, NRAS, and KRAS2, and amplification and overexpression of BRAF in MM cell lines Next, we examined the mutation status of BRAF, NRAS, and KRAS2 genes, whose mutations have been reported previously in cell lines and primary tumors of MM (Brose et al., 2002; Davies et al., 2002; Pollock et al., 2003; Smalley, 2003) . We observed two types of BRAF mutation involving exon 15: T1796A (V599E) in 26 lines and TG1796-97AT (V599D) in two lines; no mutations were observed in exon 11 (Table 1) . On the other hand, three types of mutation were present in exon 3 of NRAS, but only among five of the MM lines, and none were detected in exon 2 of KRAS2. The frequency and status of BRAF and NRAS mutations reported in MM cell lines were consistent with those we identified, except WM266mel . Thus, eight lines (20%) showed neither BRAF nor NRAS mutations, whereas the other 32 had either one or the other but not both, except for one line (697mel) where concomitant mutations were detected. These results are in accord with previous reports that those two alterations are almost entirely mutually exclusive (Brose et al., 2002; Davies et al., 2002) . We found no significant correlation between BRAF mutation status and 7q33-q34 gain (w 2 test, P ¼ 0.7365), although 3q and 20q gains occur more frequently in cells with BRAF mutation than in those with wild-type BRAF (w 2 test, 3q gain, P ¼ 0.0035; 20q,
To determine whether expression of BRAF is associated with mutation status of BRAF and/or RAS genes or 7q33-q34 gain, we next assessed expression of BRAF mRNA using real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR, Table 1 ). The 12 lines with wild-type BRAF, including four lines with only NRAS mutation, tended to express more BRAF mRNA than lines with mutant BRAF (Mann-Whitney U-test, P ¼ 0.0925, Figure 2a ), although the difference did not reach statistical significance. On the other hand, no significant difference in the expression of BRAF mRNA was observed between the five lines with NRAS mutation and lines with wild-type NRAS (Mann-Whitney U-test, P ¼ 0.6381, Figure 2b) . Notably, the eight cell lines without mutation in both BRAF and NRAS showed significantly higher expression of BRAF mRNA than cells containing their mutations (Mann-Whitney Utest, P ¼ 0.0092, Figure 2c ). However, we observed no significant difference in levels of BRAF mRNA expression between cells with and without 7q33-q34 gain (Mann-Whitney U-test, P ¼ 0.3363).
Both wild-type and mutant B-Rafs contribute to constitutive activation of MEK/ERK module in MM cells
To assess the activity of overexpressed wild-type B-Raf in MM cells, we used Western blotting to analsze the phosphorylation status of ERK1/2, the downstream effectors of the RAS-RAF-MEK-ERK pathway, under different conditions. As shown in Figure 3 , all cell lines containing wild-type BRAF and NRAS showed constitutively elevated expression of B-Raf protein compared with cells containing BRAF mutation (1011mel, MMG3, WM115mel, HS294T, 1362mel, and SK-MEL-5), cells containing NRAS mutation (1102mel and 731mel), or human normal epithelial melanocytes (HEM). In the presence of serum in culture, all cells including MM cells and HEM showed phosphorylated ERK1/2. However, in contrast to HEM, in which activated ERK1/2 were almost undetectable under serum-free culture condition, all of the MM cell lines, regardless of the mutation status of BRAF and NRAS, clearly showed phosphorylated ERK1/2 even in the absence of serum in culture ( Figure 3 ).
Overexpression of wild-type B-Raf promotes cell growth in MM cells
To determine whether the overexpressed wild-type B-Raf contributes to elevated phosphorylation of ERK1/2, thereby activating the MAPK pathway and promoting growth of MM cells, we used antisense oligonucleotide phosphorothioate (OPT) to reduce B-Raf expression in cells overexpressing wild-type B-Raf. One of the synthesized antisense OPTs for BRAF (BRAF-AS) successfully downregulated expression of To conversely examine a potential role of the overexpressing wild-type B-Raf on melanomagenesis, we investigated the functional consequences of exogenously overexpressed wild-type B-Raf in MM cell growth in vitro. In a colony formation assay using WM266mel and 537mel cells, which have wild-type BRAF and NRAS and exhibited relatively low expression of wild-type B-Raf (Table 1, Figure 3 ), transiently transfected pCMV-Tag2-BRAF-WT produced more colonies (X3 mm) than did mock control plasmid (pCMV-Tag2), although pCMV-Tag2-BRAF-Mut (V599E) produced larger number and size of colonies than both mock control and pCMV-Tag2-BRAF-WT (Figure 4f, g ). Cells were cultured in 0.1% bovine serum albumin-containing media in the presence (10%) or absence (0%) of FBS for 48 h. Wholecell protein extracts were separated by 10% SDS-PAGE, and probed with anti-B-Raf, anti-ERK1/2, anti-phospho-ERK1/2 (P-ERK1/ 2), and the internal control (anti-beta-actin) antibodies. Consistent with their mRNA expression patterns, cell lines having wild-type BRAF and RAS showed constitutively higher expression of B-Raf protein compared with lines containing BRAF or NRAS mutations. Notably, ERK1/2 was still activated under serum-free culture for 48 h in all of MM cells regardless of the mutation status of BRAF and NRAS, whereas activated ERK1/2 was almost undetectable under serum-free condition in normal melanocytes (HEM)
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Discussion
Results from our CGH analysis of 40 MM cell lines accorded well with previous CGH data in primary tumors (Bastian et al., 1998; Balazs et al., 2001) . No unique alteration was observed among the five lines established from Japanese patients compared with the others (cf Table 1 ), although clinical and histopathologic differences have been documented in patients of different ethnicities (Kukita and Ishihara, 1989) .
Among the frequent alterations we observed, gain/ amplification of 7q is the change, which is also frequently observed in primary MMs (Bastian et al., 1998; Balazs et al., 2001) . Although affected region has never been narrowed down, HLG at 7q33-qter was reported (Bastian et al., 1998) and HLG at 7q33-q34 was detected in six of 40 lines in the present study. Since BRAF gene locates in 7q34, we chose to perform further molecular cytogenetic and functional characterization of B-Raf in MM cell. and the indicated MM cell lines were treated with 2 mM of U0126, a specific inhibitor of MEK1/2, in the presence of 10% FBS for 24 h. The whole-cell extracts were subsequently analysed for phosphorylated ERK1/2 (P-ERK1/2) and total ERK1/2 levels. (e) HEM and the indicated MM cell lines were treated with 2 mM of U0126 for 72 h. Cell proliferation was measured by the colorimetric WST assay on days 0 and 3 of treatment. The percentage of inhibition was obtained by comparing treated and control cultures (Calipel et al., 2003.) . The data presented are the means7s.e. of three separate experiments, each performed in triplicate. Note that growth of normal melanocytes was not inhibited by the U0126 treatment, whereas MM cells were sensitive to the U0126 treatment regardless of the mutation status of BRAF. 
of triplicate plates
Expression of wild-type BRAF in malignant melanoma H Tanami et al B-Raf functions in the RAS-RAF-MEK-ERK pathway, and activation of this pathway is thought to be involved in the melanomagenesis. Most MM cell lines and primary tumors have shown high constitutive ERK activity, most likely as a consequence of mutations in two upstream components, RAS and B-Raf (Smalley, 2003) . Activating mutations of BRAF and RAS have been observed in 60-66 and 9-15%, respectively, of MMs, and these mutations tend to be mutually exclusive (Brose et al., 2002; Davies et al., 2002) . However, it was shown that approximately 20% of MMs do not carry any mutation in either of those genes (Brose et al., 2002; Davies et al., 2002; Pollock et al., 2003) and, so far as we know, no mutations has been found in either ERK1/2 or MEK1/2 in human tumors (Peyssonnaux and Eyche'ne, 2001; Smalley, 2003) ; therefore, other mechanisms activating the RAS-RAF-MEK-ERK pathway may participate in the pathogenesis of this disease. One published study involving cells derived from head-andneck tumors showed that amplification of wild-type KRAS2 resulted in an overactive mitogenic signal, in turn increasing the proliferative response of the tumor cells (Hoa et al., 2002) . Amplification of wild-type KRAS2 also has been associated with reduced apoptosis in germ-cell tumors (Roelofs et al., 2000) . However, the low incidence of amplification of either NRAS or KRAS2 in MMs (Bastian et al., 1998; Balazs et al., 2001 ) prompted us to hypothesize that overexpression of wild-type B-Raf, whether by amplification or any other mechanism, might contribute to both activation of the MEK/ERK module and cell proliferation in MM.
Cells containing wild-type BRAF and NRAS showed significantly higher expression of BRAF gene in transcription level than cells containing their mutations, suggesting that, instead of the activation of B-Raf or NRAS by mutation, overexpression of wild-type B-Raf may contribute to activation of the MEK/ERK module, as overexpression of wild-type KRAS2 does in other tumors (Roelofs et al., 2000; Hoa et al., 2002) . Higher expression of B-Raf in cells containing wild-type BRAF and NRAS was also observed in protein level. However, no significant correlation between copy-number gain and BRAF expression was observed, suggesting that expression of BRAF may not always be regulated in a gene-dosage manner. Although further study will be needed to clarify the regulatory mechanism of B-Raf expression, it is possible that total activity of the RAS-RAF-MEK-ERK pathway may modulate the expression levels of BRAF.
Even after the treatment with serum-free media, B-Raf that was constitutively activated through mutation of BRAF or NRAS was able to phosphorylate ERK1/2 to the same degree as those in cells grown in 10% serum in MM cells. In MM lines without mutation of either BRAF or NRAS, ERK1/2 was still activated under serum-free conditions, but not in normal melanocytes. Antisense OPT-mediated downregulation of endogenously overexpressed B-Raf reduce ERK1/2 activation and cell growth in MM lines without mutation of either BRAF or NRAS. In those cells, inhibition of the MEK/ ERK module by U0126 decreased phosphorylated ERK1/2 and cell growth, as in cells with BRAF mutation. In normal melanocytes, conversely, phosphorylation status of ERK1/2 as well as cell growth, which were sensitive to serum-free condition, were not sensitive to U0126 treatment, as shown by Calipel et al. (2003) using normal choroidal melanocytes. Moreover, wild-type B-Raf transfected into MM cells with wildtype BRAF and NRAS increased the number of larger colonies that developed from transfected cells compared to control cells transfected with the mock vector. Those observations indicate that, even possessing wild-type BRAF, activation of MEK/ERK module and growth of MM cells depend strongly on the BRAF-MEK-ERK pathway activated by overexpression of B-Raf at least in part, whereas those of normal melanocytes do not. Therefore, regardless of the mutation status of BRAF, inhibition of expression and/or kinase activity of B-Raf may be a feasible and worthwhile clinical approach to the management of MM.
Our findings provide the first evidence that, like KRAS2, non-mutated B-Raf have a growth-promoting potential when it is overexpressed in MM cells. However, since it has been shown that basal kinase activity of mutated B-Raf V599E, a major mutation in our MM cells, is 10.1-fold higher than that of wild-type B-Raf in vitro , it remains unknown how wild-type B-Raf is sufficiently activated for constitutive MEK/ERK module activation in MM cells without NRAS mutation. One possibility is that, as reported by Satyamoorthy et al. (2003) , autocrine growth factor stimulation may induce B-Raf kinase activation in cells without mutation of BRAF and NRAS. Interestingly, B-Raf possesses only two RAS-GTP-dependent phosphorylation sites for maximal activation, whereas A-Raf and C-Raf contain four of these sites, and therefore B-Raf has substantially greater basal kinase activity toward MEK/ERK module than does A-Raf or C-Raf (Chong et al., 2003; Mercer and Pritchard, 2003; Tuveson et al., 2003) , suggesting that even weak signals from cell surface may easily engender maximal and constitutive activation of the B-Raf activity. Another possibility is that nonmutated B-Raf in MM cells may stimulate MEK/ERK module through activating other molecules, including endogenous C-Raf (Wan et al., 2004) , although they reported that depleting C-Raf had little effect on ERK activity in COS cells expressing wild-type B-Raf.
The pivotal role of ERK in the oncogenesis of MM suggests that the MAPK pathway would be an ideal therapeutic target. On the other hand, our CGH experiments have revealed that gains of DNA at 3q and 20q occur more frequently in cells with BRAF mutation than in those with wild-type BRAF. Metzelaar-Blok et al. (1999) also reported that more frequent loss of heterozygosity on 6p was observed in uveal melanoma, which showed infrequent BRAF mutation (Edmunds et al., 2003) , than in cutaneous melanoma containing frequent BRAF mutation. Recently, Kumar et al. (2003) reported an inverse relation between BRAF and NRAS mutations and allelic loss on chromosome 9 in sporadic primary melanomas. Those findings suggest 
Materials and methods
Cell lines
Among the 40 human MM cell lines listed in Table 1 
CGH
CGH experiments were performed as described by Kallioniemi et al. (1992) , with minor modifications (Fukuda et al., 2000) . Test and normal DNAs were labeled, respectively, with Spectrum Green-and Orange-dUTP (Vysis, Chicago, lL, USA). Shifts in CGH profiles were rated as gains and losses if they reached at least the 1.2 and 0.8 thresholds, respectively, and over-representations were considered to be HLGs when the fluorescence ratio exceeded 1.5 (Fukuda et al., 2000) . Heterochromatic regions near centromeres, and X and Y chromosomes, were excluded from the analysis.
FISH
Metaphase chromosome slides were prepared as described previously (Ariyama et al., 1998) . PAC containing the BRAF gene (RP5-839B19) were labeled with biotin-16-dUTP by nicktranslation (Roche Diagnostics, Tokyo, Japan), and hybridized to metaphase chromosome spreads together with Cot-1.
Analysis of BRAF and RAS mutations
Exons 11 and 15 of BRAF, exon 2 of KRAS2, and exon 3 of NRAS were examined by directly sequencing genomic PCR products using an ABI377 sequencer (Applied Biosystems, Foster City, CA, USA), as described by Davies et al. (2002) .
Real-time quantitative RT-PCR
Levels of BRAF mRNA were measured by means of a realtime fluorescence detection method (Yasui et al., 2002) . Realtime quantitative PCR was performed with an ABI PRISM 7900HT (Applied Biosystems) using SYBR Green, according to the manufacturer's protocol. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as an endogenous control, and the expression level of BRAF mRNA in each sample was normalized on the basis of the respective GAPDH content. Primer sequences are available on request. PCR amplification was performed in duplicate for each sample.
Western blotting
Anti-p44/42 ERK1/2 and anti-phospho-ERK1/2 (Thr202/ Tyr204) antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-B-Raf and anti-betaactin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Sigma (St Louis, MO, USA), respectively. Cells grown in six-well dishes were starved of serum, or treated with U0126 or OPT, and subsequently lysed in a buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% sodium deoxycholate, 0.1% SDS, and 1% Triton X-100 with a protease-inhibitor cocktail (Roche Diagnostics). After the protein concentration of each lysate was estimated by BCA assay (Pierce Chemical, Rockford, IL, USA), equal amounts of proteins were separated on SDSpolyacrylamide gels (SDS-PAGE), and transferred to polyvinylidene difluoride membranes. The proteins were detected after incubation with appropriate primary antibodies and peroxidase-conjugated secondary antibodies, followed by development with an enhanced electrochemiluminescence system (Amersham, Arlington Heights, IL, USA) and LAS-3000 Image Analyzer (Fuji Film, Tokyo, Japan) with an appropriate exposure condition for each protein.
Antisense experiments and cell culture
Antisense experiments were performed as described previously (Saito-Ohara et al., 2003) . Briefly, we synthesized the following OPT (Espec Oligo Service, Tsukuba, Japan): BRAF-AS, nucleotides 106-123 of BRAF cDNA (GenBank accession number NM_004333) in the antisense direction; and BRAF-SC, the sense control for BRAF-AS. OPTs were delivered into cells using Oligofectaminet (Invitrogen). To evaluate gene expression, we plated 4x10 4 cells onto six-well dishes, transfected them, and harvested cells 48 h later. Protein levels were determined by western blotting. To measure cell growth, we seeded 4 Â 10 3 cells in 96-well plates the day before transfection; viable cells were assessed 24, 48, 72, or 96 h after transfection by the colorimetric water-soluble tetrazolium salt (WST) assay (Cell counting kit-8; Dojindo Laboratories, Kumamoto, Japan) as described elsewhere (Imoto et al., 2001) .
Colony formation assay (anchorage-dependent growth assay)
Plasmids expressing FLAG-tagged wild-type (pCMV-Tag2-BRAF-WT) and mutant (V599E) B-Raf (pCMV-Tag2-BRAFMut) were obtained by cloning full-length RT-PCR products into the pCMV-Tag2 (Stratagene, La Jolla, CA, USA) in frame along with the FLAG-epitope. pCMV-Tag2-BRAF-WT, pCMV-Tag2-BRAF-Mut, or the empty vector was transfected using FuGENE6 (Roche Diagnostics) into MM cells as described elsewhere Sonoda et al., 2004) .
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Statistical analysis
Differences in the frequency of BRAF mutations between subgroups were analysed by w 2 tests. Differences in BRAF expression levels between subgroups, and differences in cell viability between OPT-treated cells, were tested by the nonparametric Mann-Whitney U-test with determination of associated probability (P). Po0.05 was required for significance.
